STEPHEN NEAL: Open Payments
NPI 1609076538 · WAYNESBURG, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,708 in 100 payments from 12 companies in 2025. Trend: 2023 $1,101 · 2024 $1,171 · 2025 $1,708
Food & beverage: $1,708
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $381 |
| Neurocrine BioSciences, Inc. | 21 | $309 |
| Vanda Pharmaceuticals Inc. | 16 | $234 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $201 |
| Alkermes, Inc. | 8 | $157 |
| Janssen Pharmaceuticals, Inc | 8 | $137 |
| Axsome Therapeutics, Inc. | 5 | $85 |
| Supernus Pharmaceuticals, Inc. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $41 |
Products named: REXULTI, INGREZZA, CAPLYTA, ARISTADA, FANAPT, INVEGA SUSTENNA, HETLIOZ, Auvelity.
Industry payments across PA — which companies pay providers there.
